CTT to Display the Device At APS Meeting in Tampa

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that it has applied for FDA 510(k) medical device authorization for U.S. sales of its pain management therapy device. The CTT device has Medical Device CE certification from the European Union allowing European sales for this non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. CTT has exclusive worldwide rights to this patented device.

CTT will launch and display the device in the U.S. at the American Pain Society's (APS) 27th Annual Scientific Meeting in Tampa, FL on May 8 and 9, 2008 (http://www.ampainsoc.org). The APS is a multidisciplinary community that brings together scientists, clinicians and other professionals to increase the knowledge of pain and transform public policy and clinical practice to reduce pain-related suffering.

John Nano, Chairman & CEO of Competitive Technologies, explains their new breakthrough pain management system.

The therapy device, from the research of CTT client Professor Giuseppe Marineo of Delta Research & Development in Rome, treats oncological and neuropathic pain that has proven resistant to traditional drug protocols.

The non-invasive treatment from the research of CTT client Professor Marineo has already been used with successful results in seven hospitals in Italy on over 2,000 patients suffering from intense drug-resistant pain. The device has received Medical Device CE certification from the European Union as an approved electronic-analgesic apparatus. The treatment is performed by applying surface electrodes to the skin to simultaneously treat multiple pain areas.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that is has signed a letter of agreement with a billion-dollar European healthcare company in anticipation of granting them European distribution rights for CTT's pain management therapy device. The device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. It has Medical Device CE certification from the European Union allowing European sales.

Competitive Technologies, Inc. (AMEX:CTT - News) held its annual meeting of shareholders today at the American Stock Exchange in New York City. John B. Nano, CTT's Chairman, President and CEO discussed the company's performance and its portfolio of technologies. The full slide presentation is available under Investors on the CTT website: http://www.competitivetech.net.

Competitive Technologies, Inc. (AMEX:CTT - News) today announced financial results for the three and six months ended January 31, 2008.

The financial results for the second quarter ended January 31, 2008 are a net loss of approximately $1.3 million, or $0.16 per share, a 64% improvement when compared to the net loss of approximately $3.6 million, or $0.44 per share, for the prior year quarter. The net loss for the six-month period ending January 31, 2008 is $3.9 million, or $0.47 per share, a 17% improvement when compared to the net loss of $4.7 million, or $0.59 per share, for the prior-year period. Cash position at quarter end was $4.5 million, with no long-term debt.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that their client Medical College of Georgia Research Institute (MCGRI), and MCGRI's collaborator University of Georgia (UGA), and Percept BioSciences have entered into an agreement to obtain an exclusive worldwide license to develop and commercialize a patented library of novel compounds that have demonstrated superior efficacy in established non-human primate models of cognition and attention for human health applications. The technology is from the work of Drs. Jerry Buccafusco and Alvin Terry, Jr. at MCG, and Dr. J. Warren Beach at UGA. The agreement allows for varying levels of compensation to MCGRI and UGA. CTT will share in the payments to MCGRI.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that its Board of Directors has set Friday, April 18, 2008 as the date for their 2008 Annual Meeting of Shareholders.

Shareholders at the close of business on March 14, 2008, the record date, are entitled to receive notice of the Meeting and to vote their shares.

The Meeting will be held at the American Stock Exchange, 86 Trinity Place, New York, NY 10006 at 11:00 a.m. local time.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that it has signed an agreement with NTRU Cryptosystems, Inc. to exclusively represent NTRU's trusted computing and embedded security products in the Korean market. NTRU, a leading provider of embedded security software solutions, is a developer of fast, low-footprint public key cryptography.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that it has successfully reclaimed rights to its sexual dysfunction technology by terminating the license it had previously granted to Palatin Technologies, Inc. (AMEX:PTN - News). CTT now has complete control over license rights to the PT-14 sexual dysfunction technology. PTN has agreed to pay CTT an amount of $800,000 within one business day.

"CTT is continuing discussions with major pharmaceutical companies interested in licensing this innovative technology,'' said John B. Nano, CTT's Chairman, President and CEO. "CTT has always defended the patent rights of our clients, and will continue to do so. We are glad to bring this matter to a successful conclusion and to be able to focus on potential development of this technology by a major pharmaceutical company.''

Palatin Technologies, Inc. (Amex: PTN - News) announced today that it entered into an agreement to settle all outstanding litigation and disputes with Competitive Technologies, Inc. (Amex: CTT - News) related to a license agreement between the companies. Under the terms of the settlement, Palatin retains all rights to bremelanotide, its peptide in clinical development for male erectile dysfunction and female sexual dysfunction, with no obligations for any future payments to Competitive Technologies.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that it has signed a license and commercialization agreement for rights to the patented breast cancer diagnostic technology, Early Breastest(tm). The non-invasive technology generates an analysis that detects angiogenesis, an early predictor of the possibility of cancer. The agreement provides for sharing of revenue derived from the technology.

CTT Commercialization Plan Moves Forward

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that its European CE-certified pain management therapy device has been successfully used to treat pain related to herpes zoster, commonly known as shingles or zoster, in a pregnant woman in Italy. Developed by CTT's client, Prof. Giuseppe Marineo in Italy, and brought to CTT through the efforts of Prof. Giancarlo Elia Valori of the Italian business development group, Sviluppo Lazio S.p.A., CTT has exclusive worldwide rights to the therapy for a non-invasive method for rapid treatment of high-intensity oncologic, neuropathic and morphine-resistant pain through a biophysical rather than a biochemical approach. The pain management device allowed the woman, in her twenty-fifth week of pregnancy, to be successfully treated for her painful zoster outbreak in a manner that did not interfere with her condition or that of the fetus.

John Nano, President, CEO and Chairman of Competitive Technologies demonstrates the MC Square device on ABC News. The MC Square brain booster, which will help take care of all your brainwave management needs. It's a small, Walkman-sized control unit programmed with software that regulates the intensity and frequency of light and sound in combinations designed to generate changes in your brainwaves for relaxation purposes. In fact, you can tune in to several different presets and dial in any number of mental states to help increase concentration, manage stress, etc.

Competitive Technologies, Inc. (AMEX:CTT - News) today announced that the financial results of the first quarter fiscal 2008, ending October 31, 2007, were a net loss of $2.6 million, or $0.32 per share, compared to a net loss of $1.1 million, or $0.14 per share for same period of the prior year.

Competitive Technologies, Inc. announced at a media event in Seoul, Korea that together with licensee Daeyang E&C, Co., Ltd. they have launched the worldwide commercialization program for CTT's pain management therapy. The therapy device, from the research of CTT client Professor Giuseppe Marineo of Delta Research & Development in Rome, treats oncological and neuropathic pain that has proven resistant to traditional drug protocols. CTT coordinated with Professor Giancarlo Elia Valori, President of the Italian economic development group, Sviluppo Lazio, on its agreement for license rights to the pain management therapy. A multi-processor device shipped from Italy to Korea was used to treat patients in a demonstration for about 50 television and print media representatives. This device will be utilized to develop commercial production in Korea for worldwide distribution.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today at a media event in Seoul, Korea that together with licensee Daeyang E&C, Co., Ltd. (KOSDAQ:033030.KQ - News) they have launched the worldwide commercialization program for CTT's pain management therapy. The therapy device, from the research of CTT client Professor Giuseppe Marineo of Delta Research & Development in Rome, treats oncological and neuropathic pain that has proven resistant to traditional drug protocols. CTT coordinated with Professor Giancarlo Elia Valori, President of the Italian economic development group, Sviluppo Lazio, on its agreement for license rights to the pain management therapy. A multi-processor device shipped from Italy to Korea was used to treat patients in a demonstration at today's event for about 50 television and print media representatives. This device will be utilized to develop commercial production in Korea for worldwide distribution.

Delta Research & Development presents Scrambler Therapy, demonstrated by Professor Giuseppe Marineo

Competitive Technologies, Inc. (AMEX:CTT - News) and Articulated Technologies, LLC today announced that they have signed an agreement for CTT to license and commercialize Articulated's patented organic light emitting diode (OLED) technology for adaptation to solar power. The agreement provides for revenue sharing between CTT and Articulated of royalty and licensing payments.

CTT media coverage on MC Square

Competitive Technologies, Inc. has announced the launch of their MC Square product in the U.S.

The revolutionary light and sound system is designed to provide stress relief, and improve verbal memory, learning and attention. CTT has U.S. distribution rights for the patent-pending technology licensed by Thomas Jefferson University of Philadelphia (Jefferson) to Seoul, Korea-based Daeyang E&C, Inc.